EGFR and bladder transitional cell carcinoma: As an example, in bladder urothelial carcinoma, Epidermal Growth Factor Receptor (EGFR)-, K-RAS-, and RAF-dependent pathways were activated in 42%, 22%, and 38% of cases, but only three patients carried the EGFR mutation and no mutation in K-RAS or RAF was found.